Essential hypertension of mild and moderate severity. This combination drug is indicated for patients with insufficient response to zofenopril monotherapy.
The therapeutic effect of the drug in hypertension and acute myocardial infarction is based on its ability to inhibit renin-angiotensin in blood plasma. Inhibition of ACE leads to a decrease in angiotensin II in blood plasma, which leads to suppression of vasoconstrictive activity and aldosterone production. However, with a marked decrease in aldosterone levels, there may be a slight increase in serum potassium, along with fluid loss and decreased sodium levels. Suppression of the reverse effect of angiotensin II on renin secretion causes an increase in plasma renin activity. After the patient took a single oral dose, there was a decrease in ACE activity in blood plasma after 24 hours by 53.4% or 74.4%.
Composition and form of release
Tablets that are coated with an enteric film. Each tablet contains 30 mg of zofenopril calcium, equivalent to 28.7 mg of zofenopril and 12.5 mg of hydrochlorothiazide. The tablets are placed in blisters of 14 pieces, 2 blisters in a cardboard box.
It is used in the treatment of essential hypertension of mild or moderate severity.
In addition, the drug is indicated for patients who develop an insufficient response to zofenopril monotherapy.
Absolute contraindications to the drug is hypersensitivity to zofenopril, as well as other ACE inhibitors. The use of the drug is contraindicated if the patient has previously experienced the development of angioneurotic edema on the background of ACE inhibitors, as well as a history of hereditary or idiopathic angioneurotic edema.
It is not prescribed for severe liver dysfunction, pregnancy and lactation, as well as bilateral bilateral renal artery stenosis or unilateral if the patient has one kidney.
Use during pregnancy and breastfeeding
Method of application and dose
The drug is taken orally once a day, regardless of food. The dose is selected strictly individually, taking into account the response of the patient’s body to its reception.
In the treatment of arterial hypertension, the level of blood pressure must be taken into account when choosing the dose of the drug. The dose is increased once every four weeks.
If the patient does not suffer from water or salt depletion, then in the initial dosage the drug is prescribed 15 mg once a day. The dosage is increased until the blood pressure level normalizes. In most cases, the effective therapeutic dose is 30 mg. The highest daily dose is 60 mg.
Failure to observe the prescribed doses may cause the patient to develop severe hypotension, stupor, shock, bradycardia, electrolyte disturbances and renal dysfunction.
At acute poisoning the patient is shown constant control of level of electrolytes and creatinine in blood serum, gastric lavage and appointment of correct treatment. In severe cases, the introduction of drugs to increase blood plasma volume is indicated.
Sometimes the drug causes dizziness, headache, cough, dyspeptic disorders, angioneurotic edema, local allergic reactions, muscle cramps, fatigue, asthenia, hypoglycemia, depression, changes in consciousness, sleep disturbances, disorientation, paresthesia, changes in taste, visual disturbances, tinnitus and dry mouth.
Conditions and terms of storage
Zocardis Plus 30 / 12.5 is stored out of reach of children and is well protected from light and moisture. The duration of storage of the drug does not exceed 3 years.